In addition, our results indicate that the patient’s conditions potentially influencing AFP absorption at the end of the prophylactic treatment phase do not affect the need for a non-prophylactic AF treatment, which is consistent with previously published data and confirm the good biodisponibility of posaconazole [34,35]. Here, AFP is linked to atrial fibrillation.